MicroRNAs: From bench to bedside applications as breast cancer therapsseutics

IF 2.5 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2025-07-04 DOI:10.1016/j.seminoncol.2025.152386

Md Abdus Samad , Iftikhar Ahmad , Muhammad Nadeem Asghar , Mohd Suhail , Mohd Rehan , Fahad A. Al-Abbasi , Khadeejah Alsolami , Mohd Suhail Akhter , Ausaf Ahmad , Shams Tabrez

{"title":"MicroRNAs: From bench to bedside applications as breast cancer therapsseutics","authors":"Md Abdus Samad , Iftikhar Ahmad , Muhammad Nadeem Asghar , Mohd Suhail , Mohd Rehan , Fahad A. Al-Abbasi , Khadeejah Alsolami , Mohd Suhail Akhter , Ausaf Ahmad , Shams Tabrez","doi":"10.1016/j.seminoncol.2025.152386","DOIUrl":null,"url":null,"abstract":"<div><div>MicroRNAs (miRNAs) or small noncoding RNA molecules, 18–22 nucleotides long, are evolutionarily conserved and may have an impact on the behavior and progression of tumors. Cancer initiation, proliferation, invasion, and metastasis are all related to the specific deregulation of miRNAs. It also affects the genes involved in metabolism, apoptosis, cellular differentiation, and proliferation. Understanding the functional roles of miRNAs could shed light on the intricate molecular mechanism that underlie cancer growth. The purpose of this review is to investigate the presence of tumor-suppressive, oncogenic, and metastatic miRNAs in cancer cells, specifically breast cancer (BC) and how these miRNAs affect the development of BC and its subtypes. In addition, the miRNA-based therapeutic strategies and utilization of different delivery system to enhance the efficacy has also been covered. Based on our article, miRNAs appear to be cutting-edge prognostic, therapeutic, and diagnostic tools for the treatment of BC. However, several barriers, such as, delivery systems, side effects, demographic variabilities, and lengthy clinical studies needs to be optimized before these miRNAs could be routinely used in clinical settings.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 5","pages":"Article 152386"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775425000788","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

MicroRNAs (miRNAs) or small noncoding RNA molecules, 18–22 nucleotides long, are evolutionarily conserved and may have an impact on the behavior and progression of tumors. Cancer initiation, proliferation, invasion, and metastasis are all related to the specific deregulation of miRNAs. It also affects the genes involved in metabolism, apoptosis, cellular differentiation, and proliferation. Understanding the functional roles of miRNAs could shed light on the intricate molecular mechanism that underlie cancer growth. The purpose of this review is to investigate the presence of tumor-suppressive, oncogenic, and metastatic miRNAs in cancer cells, specifically breast cancer (BC) and how these miRNAs affect the development of BC and its subtypes. In addition, the miRNA-based therapeutic strategies and utilization of different delivery system to enhance the efficacy has also been covered. Based on our article, miRNAs appear to be cutting-edge prognostic, therapeutic, and diagnostic tools for the treatment of BC. However, several barriers, such as, delivery systems, side effects, demographic variabilities, and lengthy clinical studies needs to be optimized before these miRNAs could be routinely used in clinical settings.

查看原文本刊更多论文

microrna：从实验到临床应用，作为乳腺癌治疗药物

MicroRNAs （miRNAs）或小的非编码RNA分子，长18-22个核苷酸，是进化上保守的，可能对肿瘤的行为和进展有影响。癌症的发生、增殖、侵袭和转移都与mirna的特异性失调有关。它还影响参与代谢、凋亡、细胞分化和增殖的基因。了解mirna的功能作用可以揭示癌症生长背后复杂的分子机制。本综述的目的是研究肿瘤抑制、致癌和转移性mirna在癌细胞，特别是乳腺癌（BC）中的存在，以及这些mirna如何影响BC及其亚型的发展。此外，还介绍了基于mirna的治疗策略和利用不同的递送系统来提高疗效。根据我们的文章，mirna似乎是治疗BC的前沿预后、治疗和诊断工具。然而，在这些mirna在临床常规使用之前，还需要优化一些障碍，如递送系统、副作用、人口统计学变异和冗长的临床研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.